期刊
ANNUAL REVIEW OF MEDICINE
卷 61, 期 -, 页码 49-61出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-020209-171035
关键词
aspirin; thienopyridines; terutroban; thrombin receptor antagonist; ticagrelor
资金
- Astra-Zeneca
- Bayer
- Eli-Lilly
- Sanofi-Aventis
- Schering-Plough
- Servier
- Nycomed
- Brystol-Myers Squibb
- Merck
- CSL Behring
- European Commission [005033]
Mechanisms of platelet inhibition are reviewed with emphasis on the pharmacokinetic and pharmacodynamic determinants of clinical efficacy and safety of antiplatelet drugs. Current developments in antiplatelet therapy are discussed in relation to both primary and secondary prevention of atherothrombotic complications. Interindividual variability in response to antiplatelet agents and new drug targets are outlined within the context of optimizing the balance between the cardiovascular benefits and bleeding risks of antiplatelet therapy. Recent advances in the pharmacogenetics of thienopyridines open the realistic prospect of a personalized choice of die most appropriate antiplatelet agent and tailored dose adjustment for an individual patient.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据